In dogs that received adjunctive therapies, was Beclin-1 found to be predictive of treatment outcome?

• A. Yes, Beclin-1 was a strong predictor
• B. No
• C. It predicted only disease-free interval
• D. It predicted response but not survival

Answer: (A)

Beclin-1 serves as a marker linked to autophagy, a cellular process that can influence how tumor cells respond to therapy. In dogs that received adjunctive therapies, Beclin-1 levels were associated with the overall treatment outcome, making it a strong predictor of how well the patient would do with those therapies. This means its value isn’t limited to one specific endpoint like disease-free interval or response alone, but rather it helped forecast the overall prognosis after treatment. The other statements describe more restricted or absent predictive value, which doesn’t fit the data showing Beclin-1 as a robust predictor of overall outcome.